CPIX - カンバ―ランド・ファ―マシュ―ティカルズ (Cumberland Pharmaceuticals Inc.) カンバ―ランド・ファ―マシュ―ティカルズ

 CPIXのチャート


 CPIXの企業情報

symbol CPIx
会社名 Cumberland Pharmaceuticals Inc (カンバ―ランド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 カンバーランド・ファーマシューティカルズ(Cumberland Pharmaceuticals Inc.)はブランド付き処方薬製品の取得、開発及び商品化に従事する医薬品専門会社である。同社は病院ケアと消化器市場向けの処方薬製品を開発・商業化する権利の取得を中心を行う。同社の製品ポートフォリオには、アセトアミノフェン中毒向けの治療薬「Acetadote」(アセチルシステイン)注射剤、疼痛・発熱向けの注射治療薬「Caldolor」(イブプロフェン)注射剤、下剤の処方薬の1種である経口液剤「Kristalose」(ラクツロース)、並びに肝腎症候群(HRS)を患っている患者の治療のための注射剤「Hepatoren」(イフェトロバン)が含まれる。平成23年12月31日現在、「Hepatoren」は第II相臨床開発段階における。平成23年11月、同社は「Kristalose」ブランドと関連する残る権利を取得した。平成23年12月期決算期において、同社は「Hepatoren」ブランド名で開発する後期段階の製品候補の権利を取得した。   カンバ―ランド・ファ―マシュ―ティカルズは米国の医薬品会社。処方箋薬の買収、開発、商業化を行う。主に救急薬と胃腸薬に重点を置く。主な製品はアセトアミノフェン中毒治療用注射剤「アセタド―テ」、急性疼痛・発熱治療用静脈内投与イブプロフェン「カルドロ―ル」など。   
本社所在地 2525 West End Avenue Suite 950 Nashville TN 37203 USA
代表者氏名 A. J. Kazimi A.J.カジミ
代表者役職名 Chairman of the Board Principal Executive Officer
電話番号 +1 615-255-0068
設立年月日 36161
市場名 NASDAQ National Market System
ipoyear 2009年
従業員数 84人
url www.cumberlandpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cpix
adr_tso
EBITDA EBITDA(百万ドル) -2.33567
終値(lastsale) 5.8
時価総額(marketcap) 90295090.2
時価総額 時価総額(百万ドル) 89.20532
売上高 売上高(百万ドル) 41.59758
企業価値(EV) 企業価値(EV)(百万ドル) 50.49531
当期純利益 当期純利益(百万ドル) -4.84351
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cumberland Pharmaceuticals Inc. revenues increased 2% to $18.8M. Net loss before extraordinary items decreased 50% to $3.2M. Revenues reflect Caldolor increase of 22% to $6.5M Vaprisol increase of 85% to $1.8M Kristalose increase of 15% to $2.1M. Lower net loss reflects Selling and Marketing decrease of 2% to $9.7M (expense) Interest Income increase of 90% to $232K (income).

 CPIXのテクニカル分析


 CPIXのニュース

   The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data  2021/05/04 12:10:20 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV ) BioNTech SE – ADR (NASDAQ: BNTX ) (moving on momentum imparted by vaccine news flow) GT Biopharma Inc (NASDAQ: GTBP ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Lantheus Holdings Inc (NASDAQ: LNTH ) Orthopediatrics Corp (NASDAQ: KIDS ) Quest Diagnostics Incorporated (NYSE: DGX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aptinyx Inc. (NASDAQ: APTX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AVROBIO, Inc. (NASDAQ: AVRO ) (reacted to the need for conducting a registrational trial for its gene therapy candidate for Fabry disease) Aziyo Biologics, Inc. (NASDAQ: AZYO ) Celyad Oncology SA (NASDAQ: CYAD ) Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) Decibel Therapeutics, Inc.
   Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020  2021/03/09 21:05:00 PR Newswire
NASHVILLE, Tenn., March 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results. Net Revenues for the…
   Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results  2021/03/02 21:05:00 PR Newswire
NASHVILLE, Tenn., March 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update after the market closes on Tuesday, Mar. 9, 2021. A conference call and live internet…
   Scleroderma Therapeutics Market Set to Surge Significantly During 2028 | Corbus Pharmaceutical Holdings Inc., Cumberland Pharmaceuticals, Inc., Cytori Therapeutics, Inc.  2021/01/22 06:05:00 OpenPR
Global Scleroderma Therapeutics Market: Overview Global scleroderma therapeutics market is experiencing a major growth in coming years. The growth of the market is majorly driven by rising off-label use of drugs approved for symptomatic indications, for instance rheumatoid arthritis. Moreover, lack
   Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update  2020/11/10 21:05:00 PR Newswire
NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million….
   Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020  2021/03/09 21:05:00 PR Newswire
NASHVILLE, Tenn., March 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results. Net Revenues for the…
   Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results  2021/03/02 21:05:00 PR Newswire
NASHVILLE, Tenn., March 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update after the market closes on Tuesday, Mar. 9, 2021. A conference call and live internet…
   Scleroderma Therapeutics Market Set to Surge Significantly During 2028 | Corbus Pharmaceutical Holdings Inc., Cumberland Pharmaceuticals, Inc., Cytori Therapeutics, Inc.  2021/01/22 06:05:00 OpenPR
Global Scleroderma Therapeutics Market: Overview Global scleroderma therapeutics market is experiencing a major growth in coming years. The growth of the market is majorly driven by rising off-label use of drugs approved for symptomatic indications, for instance rheumatoid arthritis. Moreover, lack
   Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update  2020/11/10 21:05:00 PR Newswire
NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million….
   Cumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results  2020/11/03 21:05:00 PR Newswire
NASHVILLE, Tenn., Nov. 3, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2020 financial results and Company update after the market closes on Tuesday, Nov. 10, 2020. A conference call and live internet webcast will be…
   Scleroderma Therapeutics Market Set to Surge Significantly During 2028 | Corbus Pharmaceutical Holdings Inc., Cumberland Pharmaceuticals, Inc., Cytori Therapeutics, Inc.  2021/01/22 06:05:00 OpenPR
Global Scleroderma Therapeutics Market: Overview Global scleroderma therapeutics market is experiencing a major growth in coming years. The growth of the market is majorly driven by rising off-label use of drugs approved for symptomatic indications, for instance rheumatoid arthritis. Moreover, lack
   Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update  2020/11/10 21:05:00 PR Newswire
NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million….
   Cumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results  2020/11/03 21:05:00 PR Newswire
NASHVILLE, Tenn., Nov. 3, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2020 financial results and Company update after the market closes on Tuesday, Nov. 10, 2020. A conference call and live internet webcast will be…
   Intravenous (IV) Ibuprofen Market To See Record Break Revenue $14.2 Million By 2022 | Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc.  2020/10/05 12:31:25 OpenPR
UPDATE AVAILABLE ON-DEMAND According to the research report published by Allied Market Research, the global Intravenous (IV) Ibuprofen market is expected to register a CAGR of 20.0% from 2016 to 2022. The research includes changing market dynamics, top impacting factors, key
   Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use  2020/08/18 13:35:00 PR Newswire
NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical…

 関連キーワード  (医薬品 米国株 カンバ―ランド・ファ―マシュ―ティカルズ CPIX Cumberland Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)